Virtual Demonstrations
Request a Quote

Regions

I value being part of the largest and fastest growing user community of its kind in the world

Instem Client

India

Graph showing investment increasing from approx $300m in 2008 to approx $1.5bn by 2015As R&D spend increases towards an estimated $1.5b by 2015 by the top India Pharma companies, Instem entered the early drug development market in 2006 with its first customer, Advinus Therapeutics. This purchase preceded the establishment of a Drug Discovery and Development collaboration with Merck, in which the two companies would be working together to develop drug candidates for metabolic disorders. While Western companies are partnering in intellectual property generation and increasing the volume of study outsourcing to contract laboratories, Indian firms are working on registering their products in the US and Europe.

Supported by India’s change in patent laws and the growing recognition of skills in medicinal chemistry, these factors have led to increased demands in enabling technologies.

To complete the picture for Instem, the implementation of electronic submissions now has Indian companies looking towards proven data capture and reporting solutions that will comply with familiar standards like GLP and AALAS.

Provantis offers companies in India:

  • Reduced internal operating costs
  • Increased study throughput without increasing resources
  • Automated and integrated reporting
  • Heightened compliancy with fewer errors
  • Cost-effective pricing plans
  • Better visibility for Western clients/partnerships

To learn more about Provantis in India, please contact gary.mitchell@instem.com